Adding Relacorilant to Nab-paclitaxel Prolongs OS in Patients with Platinum-Resistant Ovarian Cancer By Ogkologos - April 21, 2026 217 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ROSELLA study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR For Early-Stage Cervical Cancer, Minimally Invasive Surgery Declining May 25, 2021 Hospital’s Team Of “Dog-Tors” Helps Sick Kids Feel Less Scared Of... January 15, 2020 Cómo los ensayos clínicos pueden llevar a un tratamiento que salve... October 12, 2023 FDA Approval of KRAS Inhibitor Sotorasib for Lung Cancer Hailed as... June 25, 2021 Load more HOT NEWS Five Questions with…Fred. How can we improve LGBTQ+ cancer care? – That Cancer Conversation... A call to action: how our Campaigns Ambassadors are shaping the... Volunteering with Pride: Brett’s award-winning involvement with Cancer Research UK
